743 related articles for article (PubMed ID: 23906669)
21. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
Neuzillet Y; Methorst C; Schneider M; Lebret T; Rouanne M; Radulescu C; Molinie V; Dreyfus JF; Pelcat V; Botto H
Urol Oncol; 2014 Nov; 32(8):1135-40. PubMed ID: 25023786
[TBL] [Abstract][Full Text] [Related]
22. Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer.
Inoue K; Fukuhara H; Shimamoto T; Kamada M; Iiyama T; Miyamura M; Kurabayashi A; Furihata M; Tanimura M; Watanabe H; Shuin T
Cancer; 2012 Feb; 118(4):1062-74. PubMed ID: 21773973
[TBL] [Abstract][Full Text] [Related]
23. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy.
Zaak D; Karl A; Knüchel R; Stepp H; Hartmann A; Reich O; Bachmann A; Siebels M; Popken G; Stief C
BJU Int; 2005 Aug; 96(2):217-22. PubMed ID: 16001963
[TBL] [Abstract][Full Text] [Related]
25. A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging.
Lee JY; Cho KS; Kang DH; Jung HD; Kwon JK; Oh CK; Ham WS; Choi YD
BMC Cancer; 2015 Aug; 15():566. PubMed ID: 26232037
[TBL] [Abstract][Full Text] [Related]
26. Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit.
Ahmad S; Aboumarzouk O; Somani B; Nabi G; Kata SG
BJU Int; 2012 Dec; 110(11 Pt B):E596-600. PubMed ID: 22758907
[TBL] [Abstract][Full Text] [Related]
27. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.
Witjes JA; Redorta JP; Jacqmin D; Sofras F; Malmström PU; Riedl C; Jocham D; Conti G; Montorsi F; Arentsen HC; Zaak D; Mostafid AH; Babjuk M
Eur Urol; 2010 Apr; 57(4):607-14. PubMed ID: 20116164
[TBL] [Abstract][Full Text] [Related]
28. Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.
Tandogdu Z; Lewis R; Duncan A; Penegar S; McDonald A; Vale L; Shen J; Kelly JD; Pickard R; N Dow J; Ramsay C; Mostafid H; Mariappan P; Nabi G; Creswell J; Lazarowicz H; McGrath J; Taylor E; Clark E; Maclennan G; Norrie J; Hall E; Heer R;
BMJ Open; 2019 Sep; 9(9):e022268. PubMed ID: 31481549
[TBL] [Abstract][Full Text] [Related]
29. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
Daneshmand S; Schuckman AK; Bochner BH; Cookson MS; Downs TM; Gomella LG; Grossman HB; Kamat AM; Konety BR; Lee CT; Pohar KS; Pruthi RS; Resnick MJ; Smith ND; Witjes JA; Schoenberg MP; Steinberg GD
Nat Rev Urol; 2014 Oct; 11(10):589-96. PubMed ID: 25245244
[TBL] [Abstract][Full Text] [Related]
30. Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over.
Soria F; Gurioli A; Peraldo F; Oderda M; Giona S; Ambrosini E; Frea B; Gontero P
Urologia; 2013 Jun; 80 Spec No 1():1-8. PubMed ID: 23813287
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis.
Chen C; Huang H; Zhao Y; Liu H; Sylvester R; Lin T; Huang J
BMJ Open; 2019 Oct; 9(10):e028173. PubMed ID: 31628123
[TBL] [Abstract][Full Text] [Related]
32. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.
Witjes JA; Douglass J
Nat Clin Pract Urol; 2007 Oct; 4(10):542-9. PubMed ID: 17921969
[TBL] [Abstract][Full Text] [Related]
33. Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT.
Fukuhara H; Yamamoto S; Lai HW; Karashima T; Kurabayashi A; Furihata M; Inoue K
Photodiagnosis Photodyn Ther; 2022 Jun; 38():102757. PubMed ID: 35151889
[TBL] [Abstract][Full Text] [Related]
34. The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.
Renninger M; Fahmy O; Schubert T; Schmid MA; Hassan F; Stenzl A; Gakis G
World J Urol; 2020 Feb; 38(2):397-406. PubMed ID: 31030231
[TBL] [Abstract][Full Text] [Related]
35. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.
Malmström PU; Grabe M; Haug ES; Hellström P; Hermann GG; Mogensen K; Raitanen M; Wahlqvist R
Scand J Urol Nephrol; 2012 Apr; 46(2):108-16. PubMed ID: 22087730
[TBL] [Abstract][Full Text] [Related]
36. Value of fluorescence cystoscopy in high risk non-muscle invasive bladder cancer.
Mayr R; Burger M
Curr Urol Rep; 2013 Apr; 14(2):90-3. PubMed ID: 23341375
[TBL] [Abstract][Full Text] [Related]
37. Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer.
Kobayashi K; Matsuyama H; Oka S; Nakamura K; Misumi T; Hiroyoshi T; Ito H; Isoyama N; Hirata H; Matsumoto H; Shiraishi K
Photodiagnosis Photodyn Ther; 2023 Mar; 41():103294. PubMed ID: 36681259
[TBL] [Abstract][Full Text] [Related]
38. Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.
Matsushita Y; Miyake M; Nishimura N; Nishimoto K; Fukuhara H; Kobayashi K; Oyama M; Inoue K; Matsuyama H; Fujimoto K; Miyake H
Int J Clin Oncol; 2024 Feb; 29(2):205-212. PubMed ID: 38112832
[TBL] [Abstract][Full Text] [Related]
39. Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience.
Lacetera V; Cantoro U; Montesi L; Cantoro D; Cervelli B; Cicetti A; Gabrielloni G; Milella D; Montesi M; Morcellini R; Parri G; Recanatini E; Beatrici V
Arch Ital Urol Androl; 2017 Mar; 89(1):39-41. PubMed ID: 28403596
[TBL] [Abstract][Full Text] [Related]
40. Hexyl aminolevulinate: in the detection of bladder cancer.
Frampton JE; Plosker GL
Drugs; 2006; 66(4):571-8; discussion 579-80. PubMed ID: 16597168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
